Exclusive Summary

• Recommended as a universally recognized first-line antihypertensive and listed in the WHO Essential Medicines, effectively targeting a rigid demand from over 1.3 billion global patients.
• Completely free of patent barriers, allowing global distribution partners to quickly launch and commercialize the product with zero intellectual property risks.
• Leveraging massive manufacturing scale, the Chinese supply chain offers extreme cost-effectiveness, serving as a highly competitive asset for winning governmental and institutional public tenders.
• Backed by international quality standards (USP/EP/BP) and comprehensive CTD dossiers, ensuring rapid overseas regulatory registration and a highly reliable, shortage-free supply.